nach oben

Erschienen in:

01.12.2015 | Original Research

Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy

verfasst von: Matteo Santoni, Sebastiano Buti, Alessandro Conti, Camillo Porta, Giuseppe Procopio, Cora N. Sternberg, Sergio Bracarda, Umberto Basso, Ugo De Giorgi, Mimma Rizzo, Lisa Derosa, Cinzia Ortega, Francesco Massari, Michele Milella, Melissa Bersanelli, Linda Cerbone, Giovanni Muzzonigro, Luciano Burattini, Rodolfo Montironi, Daniele Santini, Stefano Cascinu

Erschienen in: Targeted Oncology | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

We aimed to assess the prognostic role of pretreatment neutrophilia, lymphocytopenia, and neutrophil to lymphocyte ratio (NLR) in patients treated with vascular endothelial growth factor-tyrosine kinase inhibitors (VEGFR-TKIs) for late relapsing (>5 years) metastatic renal cell carcinoma (mRCC). Data were collected from 13 Italian centers involved in the treatment of metastatic RCC. Late relapse was defined as >5 years after initial radical nephrectomy. One hundred fifty-one patients were included in this analysis. Among them, MSKCC risk score was favorable in 68 %, intermediate in 29 %, and poor in 3 %. Fifty-six patients (37 %) had NLR ≥3 at the start of VEGFR-TKI therapy (group A), while 95 had lower NLR (63 %, group B). The median overall survival (OS) was 28.8 months in group A and 68.7 months (95 % confidence interval (CI) 45.3–NA) in group B (p < 0.001). The median progression-free survival (PFS) was 15.8 months in group A and 25.1 months in group B (p = 0.03). At multivariate analysis, MSKCC risk group and NLR were independent prognostic factors for both OS and PFS. Pretreatment NLR is an independent prognostic factor for patients with late relapsing mRCC treated with first-line VEGFR-TKIs. A better characterization of baseline immunological impairment may optimize the management of this RCC subpopulation.

Nur mit Berechtigung zugänglich

Kaelin WG (2004) The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 10:6290S–6295SCrossRefPubMed

Santoni M, Santini D, Massari F, Conti A, Iacovelli R, Burattini L, Tortora G, Falconi M, Montironi R, Cascinu S (2014) Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. Cancer Metastasis Rev 33:321–331CrossRefPubMed

Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Eng J Med 366:883–892CrossRef

Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444CrossRefPubMed

Mantovani A, Cassatella MA, Costantini C, Jaillon S (2011) Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 11:519–531CrossRefPubMed

McNichols DW, Segura JW, DeWeerd JH (1981) Renal cell carcinoma: long-term survival and late recurrence. J Urol 126:17–23PubMed

Nakano E, Fujioka H, Matsuda M, Osafune M, Takaha M, Sonoda T (1984) Late recurrence of renal cell carcinoma after nephrectomy. Eur Urol 10:347–349PubMed

Miyao N, Naito S, Ozono S, Shinohara N, Masumori N, Igarashi T, Nakao M, Tsushima T, Senga Y, Horie S, Kanayama HO, Tokuda N, Kobayashi M (2011) Late recurrence of renal cell carcinoma: retrospective and collaborative study of the Japanese Society of Renal Cancer. Urology 77:379–384CrossRefPubMed

Santoni M, Conti A, Porta C, Procopio G, Sternberg CN, Basso U, De Giorgi U, Bracarda S, Rizzo M, Ortega C, Massari F, Iacovelli R, Derosa L, Masini C, Milella M, Di Lorenzo G, Atzori F, Pagano M, Buti S, De Vivo R, Mosca A, Rossi M, Paglino C, Verzoni E, Cerbone L, Muzzonigro G, Falconi M, Montironi R, Burattini L, Santini D, Cascinu S (2014) Sunitinib, pazopanib or sorafenib for the treatment of patients with late-relapsing (>5 years) metastatic renal cell carcinoma. J Urol. doi:10.1016/j.juro.2014.07.011

10.

Kroeger N, Choueiri TK, Lee JL, Bjarnason GA, Knox JJ, MacKenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK, Yuasa T, Donskov F, Agarwal N, Tan MH, Bamias A, Kollmannsberger CK, North SA, Rini BI, Heng DY (2014) Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. Eur Urol 65:1086–1092CrossRefPubMed

11.

Heng DY, Xie W, Regan M, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor- targeted agents: results from a large, multicenter study. J Clin Oncol 27:5794–5799CrossRefPubMed

12.

Fox P, Hudson M, Brown C, Lord S, Gebski V, De Souza P, Lee CK (2013) Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. Br J Cancer 109:147–153PubMedCentralCrossRefPubMed

13.

Kobayashi M, Kubo T, Komatsu K, Fujisaki A, Terauchi F, Natsui S, Nukui A, Kurokawa S, Morita T (2013) Changes in peripheral blood immune cells: their prognostic significance in metastatic renal cell carcinoma patients treated with molecular targeted therapy. Med Oncol 30:556CrossRefPubMed

14.

Ohno Y, Nakashima J, Ohori M, Gondo T, Hatano T, Tachibana M (2012) Follow up of neutrophil-to-lymphocyte ratio and recurrence of clear cell renal cell carcinoma. J Urol 187:411–417CrossRefPubMed

15.

Ohno Y, Nakashima J, Ohori M, Hatano T, Tachibana M (2010) Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with non-metastatic renal cell carcinoma. J Urol 184:873–878CrossRefPubMed

16.

Keizman D, Ish-Shalom M, Huang P, Eisenberger MA, Pili R, Hammers H, Carducci MA (2012) The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer 48:202–208PubMedCentralCrossRefPubMed

17.

Santoni M, De Giorgi U, Iacovelli R, Conti A, Burattini L, Rossi L, Luca Burgio S, Berardi R, Muzzonigro G, Cortesi E, Amadori D, Cascinu S (2013) Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma. Br J Cancer 109:1755–1759PubMedCentralCrossRefPubMed

18.

Fagerland MW, Hosmer DW, Bofin AM (2008) Multinomial goodness-of-fit tests for logistic regression models. Stat Med 27:4238–4253CrossRefPubMed

19.

Mickey RM, Greenland S (1989) The impact of confounder selection criteria on effect estimation. Am J Epidemiol 129:125–137PubMed

20.

Roxburgh CS, McMillan DC (2010) Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 6:149–163CrossRefPubMed

21.

Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ (2013) The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol 88:218–230CrossRefPubMed

22.

Tsavaris N, Baxevanis C, Kosmidis P (1996) The prognostic significance of immune changes in patients with renal cell carcinoma, malignant melanoma and colorectal carcinoma treated with IFNalpha2b. Cancer Immunol Immunother 43:94–104CrossRefPubMed

23.

Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30:1073–1081CrossRefPubMed

24.

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674CrossRefPubMed

25.

Jensen HK, Donskov F, Marcussen N, Nordsmark M, Lundbeck F, von der Maase H (2009) Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol 27:4709–4717CrossRefPubMed

26.

Buti S, Rovere RK, Donini M, Passalacqua R, Pezzuolo D, Buzio C (2012) Changes in lymphocyte count induced by repeated cycles with low-dose interleukin-2 and interferon-α in 146 patients with renal cell carcinoma. Tumori 98:45–52PubMed

27.

De Martino M, Klatte T, Seemann C, Waldert M, Haitel A, Schatzl G, Remzi M, Weibl P (2013) Validation of serum C-reactive protein (CRP) as an independent prognostic factor for disease-free survival in patients with localised renal cell carcinoma (RCC). BJU Int 111:E348–E353CrossRefPubMed

28.

Steffens S, Köhler A, Rudolph R, Eggers H, Seidel C, Janssen M, Wegener G, Schrader M, Kuczyk MA, Schrader AJ (2012) Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients. BMC Cancer 12:399PubMedCentralCrossRefPubMed

29.

Pichler M, Hutterer GC, Stoeckigt C, Chromecki TF, Stojakovic T, Golbeck S, Eberhard K, Gerger A, Mannweiler S, Pummer K, Zigeuner R (2013) Validation of the pre-treatment neutrophil lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. Br J Cancer 108:901–907PubMedCentralCrossRefPubMed

30.

Hatakeyama S, Yoneyama T, Hamano I, Murasawa H, Narita T, Oikawa M, Hagiwara K, Noro D, Tanaka T, Tanaka Y, Hashimoto Y, Koie T, Ohyama C (2013) Prognostic benefit of surgical management in renal cell carcinoma patients with thrombus extending to the renal vein and inferior vena cava: 7-year experience at a single center. BMC Urol 13:47PubMedCentralCrossRefPubMed

31.

Sejima T, Iwamoto H, Morizane S, Hinata N, Yao A, Isoyama T, Saito M, Takenaka A (2013) The significant immunological characteristics of peripheral blood neutrophil-to-lymphocyte ratio and Fas ligand expression incidence in nephrectomized tumor in late recurrence from renal cell carcinoma. Urol Oncol 31:1343–1349CrossRefPubMed

Titel: Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy
verfasst von: Matteo Santoni
Sebastiano Buti
Alessandro Conti
Camillo Porta
Giuseppe Procopio
Cora N. Sternberg
Sergio Bracarda
Umberto Basso
Ugo De Giorgi
Mimma Rizzo
Lisa Derosa
Cinzia Ortega
Francesco Massari
Michele Milella
Melissa Bersanelli
Linda Cerbone
Giovanni Muzzonigro
Luciano Burattini
Rodolfo Montironi
Daniele Santini
Stefano Cascinu
Publikationsdatum: 01.12.2015
Verlag: Springer International Publishing
Erschienen in: Targeted Oncology / Ausgabe 4/2015
Print ISSN: 1776-2596
Elektronische ISSN: 1776-260X
DOI: https://doi.org/10.1007/s11523-014-0356-3

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy

Abstract

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2015

Detection of KIT and PDGFRA mutations in the plasma of patients with gastrointestinal stromal tumor

Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo

Renal Toxicities of Targeted Therapies

Antisense inhibition of microRNA-21 and microRNA-221 in tumor-initiating stem-like cells modulates tumorigenesis, metastasis, and chemotherapy resistance in pancreatic cancer

Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study

Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie